Status:

ACTIVE_NOT_RECRUITING

Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to better understand prostate cancer changes after radiation treatment, through magnetic resonance imaging (MRI). MRI is an imaging test that allows doctors to see prostat...

Eligibility Criteria

Inclusion

  • Patients with biopsy proven (completed and/or reviewed at MSK) adenocarcinoma of the prostate, who will undergo external beam radiotherapy using conventional fractionation IGRT including moderate hypofractionated radiation, low rate brachytherapy alone, brachytherapy (either high dose or low dose) combined with supplemental image guided radiation (including IGRT, EBRT, and SBRT), SBRT, or proton radiotherapy.
  • Age ≥ 18 years old
  • Baseline MP-MRI, which is obtained at MSKCC Main Campus on the 3-Tesla Philips MRI unit as part of the standard (clinical) staging assessment demonstrates at least one dominant or visible lesion which measures \> 0.5 cm in maximum axial diameter as assessed on T2-weighted images.
  • No prior history of androgen deprivation therapy within the last month. However patients who will receive neoadjuvant and concurrent and adjuvant hormonal therapy will be eligible.
  • Willing to come to MSK Main Campus for baseline and follow-up MP-MRIs.

Exclusion

  • History of radical prostatectomy
  • Patients who are unwilling or unable to undergo MRI including patients with contraindications to MRI such as the presence of cardiac pacemakers or non-compatible intracranial vascular clips, claustrophobia, inability to lie flat for the duration of the study etc.
  • Patients with a metallic hip implant, metallic implant or device in the pelvis or ferromagnetic fiducial beacons (Calypso) that might distort local magnetic field and compromise quality of MP-MRI
  • Patients in which gadolinium contrast is contra-indicated.
  • Metastatic disease

Key Trial Info

Start Date :

December 1 2014

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2025

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT02312401

Start Date

December 1 2014

End Date

December 1 2025

Last Update

October 6 2025

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States, 07920

2

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, United States, 07748

3

Memorial Sloan Kettering Bergen

Montvale, New Jersey, United States, 07645

4

Memorial Sloan Kettering Commack

Commack, New York, United States, 11725